2 not yet recruiting, 2 recruiting, 1 active not recruiting, 1 completed. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Completed 1 |
Follow Ileitis: new trials by email Literature Review of Ileitis trials Research Report on Ileitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery 5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis | Phase 4 | Not yet recruiting | University Hospital, Linkoeping | 110 | 2027-04-01 | 2026-08-19 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Guselkumab, Diet - Pouchitis | Phase 4 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 20 | 2026-04-23 | 2026-05-05 |
| Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) - Pouchitis, Pouches, Ileoanal | Phase 4 | Active not recruiting | University of North Carolina, Chapel Hill | 25 | 2025-08-12 | 2026-10-29 |
| Rifaximin for the Secondary Prevention of Recurrent Pouchitis Rifaximin 550 MG Oral Tablet [XIFAXAN] - Pouchitis | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 16 | 2024-07-01 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis Vedolizumab Placebo, Ciprofloxacin, Vedolizumab - Pouchitis | Phase 4 | Completed | Takeda | 102 | 2016-10-12 | 2022-02-24 |
Pouchitis (6) · Colitis, Ulcerative (2) · Calciphylaxis (1) · Craniocerebral Trauma (1) · Crohn Disease (1) · Enterocolitis, Pseudomembranous (1) · Epidermolysis Bullosa (1) · Frostbite (1) · Graft vs Host Disease (1) · Hypospadias (1) · Invasive Fungal Infections (1) · Multiple Sclerosis (1) · Myositis, Inclusion Body (1) · Optic Neuropathy, Ischemic (1) · Osteonecrosis (1)
Digestive System Diseases (6) · Enteritis (6) · Gastroenteritis (6) · Gastrointestinal Diseases (6) · Ileal Diseases (6) · Intestinal Diseases (6) · Colitis (2) · Colonic Diseases (2) · Inflammatory Bowel Diseases (2) · Arterial Occlusive Diseases (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1)
Ciprofloxacin (1) · Diet (1) · Oxygen (1) · Rifaximin (1) · Tablets (1) · guselkumab (1) · vedolizumab (1)
University of North Carolina, Chapel Hill (2) · Jay C. Buckey Jr. (1) · Takeda (1) · Universitaire Ziekenhuizen KU Leuven (1) · University Hospital, Linkoeping (1)
United States (3) · Belgium (2) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Edward Barnes, MD, MPH (2) · Jay Buckey (1)
2015 (1), R03DK140415 (1)